WO2022038386A1 - Synthèse d'acides nucléiques à support solide de type polyacrilamide - Google Patents

Synthèse d'acides nucléiques à support solide de type polyacrilamide Download PDF

Info

Publication number
WO2022038386A1
WO2022038386A1 PCT/GB2021/052189 GB2021052189W WO2022038386A1 WO 2022038386 A1 WO2022038386 A1 WO 2022038386A1 GB 2021052189 W GB2021052189 W GB 2021052189W WO 2022038386 A1 WO2022038386 A1 WO 2022038386A1
Authority
WO
WIPO (PCT)
Prior art keywords
acrylamide
monomer
solid support
initiator
polymer
Prior art date
Application number
PCT/GB2021/052189
Other languages
English (en)
Inventor
Tobias William Barr Ost
Gordon Ross MCINROY
Zachary Beyer GABER
Harold Swerdlow
Cecilia TOGNOLONI
Original Assignee
Nuclera Nucleics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuclera Nucleics Ltd filed Critical Nuclera Nucleics Ltd
Priority to EP21769161.7A priority Critical patent/EP4200411A1/fr
Publication of WO2022038386A1 publication Critical patent/WO2022038386A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1264—DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal nucleotidyl transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07031—DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal deoxynucleotidyl transferase

Definitions

  • the invention relates to methods of enzymatic solid-supported nucleic acid synthesis that make use of terminal deoxynucleotidyl transferase (TdT) enzymes.
  • the invention further relates to the use of kits comprising said enzymes in a method of solid-supported nucleic acid synthesis.
  • Nucleic acid synthesis is vital to modern biotechnology. The rapid pace of development in the biotechnology arena has been made possible by the scientific community's ability to artificially synthesise DNA, RNA and proteins.
  • DNA synthesis technology does not meet the demands of the biotechnology industry. Despite being a mature technology, it is practically impossible to synthesise a DNA strand greater than 200 nucleotides in length with a desirable yield, and most DNA synthesis companies only offer up to 120 nucleotides.
  • an average protein-coding gene is of the order of 2000- 3000 contiguous nucleotides, a chromosome is at least a million contiguous nucleotides in length and a eukaryotic genome can be in the billions of nucleotides.
  • DNA cannot be readily synthesised beyond 200 nucleotides at a time is due to the current methodology for generating DNA, which uses synthetic chemistry (i.e., phosphoramidite technology) to couple a nucleotide one at a time to make DNA. Even if the efficiency of each nucleotide-coupling step is 99% efficient, it is mathematically impossible to synthesise DNA longer than 200 nucleotides in acceptable yields.
  • the Venter Institute illustrated this laborious process by spending 4 years and 20 million USD to synthesise the relatively small genome of a bacterium.
  • Known methods of DNA sequencing use template-dependent DNA polymerases to add 3'-reversibly terminated nucleotides to a growing double-stranded substrate.
  • each added nucleotide contains a dye, allowing the user to identify the exact sequence of the template strand.
  • this technology is able to produce strands of between 500-1000 bps long.
  • this technology is not suitable for de novo nucleic acid synthesis because of the requirement for an existing nucleic acid strand to act as a template.
  • TdT has not been shown to efficiently add nucleoside triphosphates containing 3'-O- reversibly terminating moieties for building up a nascent single-stranded DNA chain necessary for a de novo synthesis cycle.
  • a 3'-O- reversible terminating moiety would prevent a terminal transferase like TdT from catalysing the nucleotide transferase reaction between the 3'-end of a growing DNA strand and the 5'-triphosphate of an incoming nucleoside triphosphate.
  • modified terminal deoxynucleotidyl transferases that readily incorporate 3'-O- reversibly terminated nucleotides.
  • Said modified terminal deoxynucieotidyl transferases can be used to incorporate 3'-O- reversibly terminated nucleotides in a fashion useful for biotechnology and single-stranded DNA synthesis processes in order to provide an improved method of nucleic acid synthesis that is able to overcome the problems associated with currently available methods.
  • Solid-phase techniques are widely used in peptide synthesis, oligonucleotide synthesis, oligosaccharide synthesis and combinatorial chemistry. Solid-phase synthesis is carried out on a solid support which is held in such a way as to enable all reagents and solvents to pass through freely during a reaction. Solid-phase synthesis has a number of advantages over solution synthesis, including:
  • Solid supports are insoluble particles to which an oligonucleotide may be bound during the nucleic acid synthesis process.
  • a number of solid support surface types and materials are known in the art. Methods of enzymatic solid-supported nucleic acid synthesis known in the art often lead to poor yield thus limiting the number of nucleotides that can be successfully synthesised. There therefore exists a need for methods of enzymatic solid-supported nucleic acid synthesis that are amenable to high-yielding nucleic acid synthesis.
  • EP3249057 Al discloses method for forming polymerized matrix array in isolated wells of a solid support. The wells are coated with initiating monomers in order to coat the wells.
  • WO 2005/065814 Al discloses a polyacrylamide hydrogel made with a functionalized monomer for subsequent coupling.
  • WO 2020/016606 Al (Oxford Nanopore Tech Ltd) discloses methods of synthesizing polynucleotides on a variety of solid supports.
  • WO 2020/150143 Al (Camena Bioscience Ltd), WO 2020/165137 Al (DNA Script), WO 2018/215803 Al (Nuclera Nucleics Ltd), WO 2019/053443 Al (Nuclera Nucleics Ltd) all disclose methods for template independent nucleic acid synthesis where the nucleic acid can be immobilised.
  • Figure 1 Annotated PAGE gel image for N+l addition reactions
  • Figure 1 shows denaturing polyacrylamide gel electrophoresis (PAGE) analysis of oligonucleotides prepared using the methods of the invention. The importance of polymer preparation is clearly shown.
  • PAGE denaturing polyacrylamide gel electrophoresis
  • Figure 2 shows a quantitative analysis of the PAGE image in Figure 1.
  • Figure 3 shows denaturing polyacrylamide gel electrophoresis (PAGE) analysis of oligonucleotides.
  • Figure 3 shows the PAGE image for N+12 addition reactions performed on different PAC-BRAC polymer coated bead types (PCM02-07).
  • X-ray photoelectron spectroscopy of coated and uncoated silica beads.
  • PAC-BRAC polymerisation and coating was performed in situ with silica paramagnetic particles.
  • X- ray photoelectron spectroscopy was used to analyse the surface chemistry of silica beads with (Panel B) and without (Panel A) a PAC-BRAC coating.
  • the atomic % of oxygen (O), nitrogen ( N ), carbon (C), and silicon (Si) was determined and used to establish the presence of a polyacrylamide coating on the surface of the silica paramagnetic particles. Comparing the atomic % of carbon and nitrogen between the uncoated and coated samples (Panel C), as well as the ratio of carbon and nitrogen, clearly shows the presence of a polyacrylamide-based surface coating.
  • FIG. 5 Denaturing polyacrylamide gel electrophoresis analysis of oligonucleotides prepared using the methods of the invention. Cleaned silica paramagnetic particles were coated with prepolymerised PAC-BRAC for ninety minutes with periodic vortexing. The coated particles were washed with 10 mM potassium phosphate pH 7. A phosphorothioate-containing oligonucleotide of SEQ 2 was coupled to the PAC-BRAC surface in a 60 minute incubation at 52°C. The oligonucleotide-coated particles were split into three aliquots and washed with different solutions to remove non-specifically bound oligonucleotide.
  • the particles were exposed to a solution containing uracil DNA glycosylase (UDG) and N,N'-dimethylethylenediamine (DMED) to cleave the oligonucleotide at the U base.
  • UDG uracil DNA glycosylase
  • DMED N,N'-dimethylethylenediamine
  • cy3 cyanine 3
  • Lane 1 Control lane. Oligonucleotide was exposed to the UDG/DMED cleavage solution. The higher molecular weight band is uncut oligonucleotide and the lower molecular weight band is cut oligonucleotide.
  • Lane 2 PAC-BRAC beads washed with 1 M aqueous sodium chloride, 0.1 % tween- 20, and 20 mM HEPES KOH. The presence of bands in the gel shows that DNA was bound to the particles. The presence of full-length (uncut) oligonucleotide suggests some non-specific binding was present. Lane 3: PAC-BRAC beads washed with 20 mM aqueous sodium hydroxide.
  • FIG. 6 Denaturing polyacrylamide gel electrophoresis (PAGE) analysis of DNA products synthesised from a selection of solid supports. DNA synthesis was performed enzymatically using an engineered terminal deoxynucleotidyl transferase (TdT) to incorporate reversibly terminated nucleotides into a growing single stranded DNA (ssDNA) product. For each surface, 0, 10, 20, 30, 40, and 50 cycles of synthesis were performed in separate experiments.
  • TdT engineered terminal deoxynucleotidyl transferase
  • Synthesis initiators were grafted to the solid supports as follows: (1) l-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) coupling to carboxyl surface, followed by capping with tris(hydroxymethyl)aminomethane (Carboxy-T) or ethanolamine (Carboxy-EA); (2) affinity interaction between a biotinylated initiator and a neutravidin surface (Neutraividin); (3) reaction between a phosphorothioate-containing initiator and a haloacetimide containing surface (PAC-BRAC). (H) and (L) indicate high and low initiator loading densities respectively. The synthesis process is markedly more efficient when performed on the PAC- BRAC surface, as evidenced by the primary product being the target product in all experiments (in contrast to other surfaces) and the significant reduction in N-l, N-2, etc deletion products.
  • EDC l-Ethyl-3-(3-dimethylaminopropyl)car
  • Figure 7 The effect of first co-monomer identity on polymer performance.
  • xPAC-BRAC (where xPAC indicates that the first co-monomer was varied) was-pre-polymerised and coated onto silica paramagnetic particles.
  • the first co-monomer was selected from acrylamide, N- (hydroxylmethyl)acrylamide, N-(hydroxyethyl)acrylamide, N,N'-dimethyl acrylamide, and N- [tris(hydroxymethyl)methyl]acrylamide.
  • acrylamide N- (hydroxylmethyl)acrylamide
  • N-(hydroxyethyl)acrylamide N,N'-dimethyl acrylamide
  • N- [tris(hydroxymethyl)methyl]acrylamide At 100% alternative monomer, there was complete replacement of acrylamide, while at 50% alternative monomer 50% acrylamide was present.
  • Synthesis initiators were then grafted to the polymer and 17 cycles of DNA synthesis were performed using an engineered terminal deoxynucleotidyl transferase and reversibly terminated nucleotides.
  • the synthesised DNA was then cleaved from the solid support and prepared into a library and sequenced on an Illumina iSeq. The percentage of reads with the correct length and sequence identity was calculated for each sample. All samples were then normalised to the value obtained when using acrylamide as the first co-monomer.
  • the data clearly shows that the identity of the first co-monomer can be varied to alter the properties of the polymer coating on a solid support. Indeed, certain compositions exceed the performance obtained when using acrylamide as the first co-monomer. Note that values shown are the average of two technical duplicates.
  • FIG. 8 Denaturing polyacrylamide gel electrophoresis (PAGE) analysis of oligonucleotides prepared using the methods of the invention in a frit-retained beads format.
  • Polymer coated beads were prepared using the method described herein. Beads were loaded into either wells of a 96-well plate with a 0.22 micron frit or 384-well plate with a 0.45 micron frit (Millipore HTS plates).
  • DNA synthesis was performed enzymatically using an engineered terminal deoxynucleotidyl transferase (TdT) to incorporate reversibly terminated nucleotides into a growing single stranded DNA (ssDNA) product.
  • TdT engineered terminal deoxynucleotidyl transferase
  • NAM addition solution
  • wash solution nitrite deblock solution
  • NDS nitrite deblock solution
  • the polymer coated silica particles were retained in the wells due to their size (> 1 micron) being greater than the frit pore size of 0.22 micron or 0.45 micron.
  • Lane 1 of the gel shows the DNA initiator (N);
  • lane 2 shows the product after 8 cycle of enzymatic DNA synthesis (N+8) on a 96-well plate with 0.22 micron frit;
  • lane 3 shows the product after 8 cycles of enzymatic DNA synthesis (N+8) on a 384-well plate with 0.45 frit.
  • the major product in lanes 2 and 3 is the N+8 oligonucleotide.
  • the fainter bands below (N+7) and above (N+8) arise due to incomplete enzymatic addition and multiple addition within one cycle respectively.
  • FIG. 9 Denaturing polyacrylamide gel electrophoresis (PAGE) analysis of oligonucleotides prepared using the methods of the invention in a polymer coated frit format.
  • the glass fibre frits of a multiwell plate were cleaned with 80% Decon, IM NaOH, and 0.1M HCI in sequence.
  • the frit was coated with prepolymerised PAC-BRAC polymer by repeated 60 second incubations and vacuum solution removal. Oligonucleotide with phosphorothioate linkages was then grafted to the polymer to act as an initiator for enzymatic DNA synthesis.
  • DNA synthesis was performed enzymatically using an engineered terminal deoxynucleotidyl transferase (TdT) to incorporate reversibly terminated nucleotides into a growing single stranded DNA (ssDNA) product.
  • TdT engineered terminal deoxynucleotidyl transferase
  • NAM addition solution
  • wash solutions wash solutions
  • deblock solution NDS
  • PAGE polyacrylamide gel electrophoresis
  • Lanes 1-3 contain DNA initiator (N); lanes 4-6 contain the products after 8 cycles of enzymatic DNA synthesis. The major product in lanes 4-6 is N+8 corresponding to the full-length synthesis product.
  • Figure 10. Synthesis on a solid support entirely comprising polymerised material. Acrylamide was polymerised together with an oligonucleotide bearing a 5' methacrylate moiety to form polymer beads incorporating pendant oligonucleotide initiators. The polymer beads were subjected to eight cycles of enzymatic DNA synthesis using an engineered terminal deoxynucleotidyl transferase and reversibly terminated nucleotides.
  • the synthesised material was prepared into a library and sequenced on an Illumina iSeq. The percentage of initiators that had cumulatively undergone correct addition was calculated and plotted for each synthesis cycle.
  • the data clearly shows that a solid support comprising only polymerised material (i.e. not coated onto an existing solid material) is a suitable solid support for enzymatic DNA synthesis.
  • the inventors In the process of testing suitable solid supports for TdT based extension reactions, the inventors have identified particular supports which are surprisingly advantageous in terms of the efficiency of extension.
  • the inventors have identified methods of enzymatic solid-supported nucleic acid synthesis that offer improved yield and specificity for target products relative to methods known in the art.
  • the inventors have identified solid support coatings for use in enzymatic solid-supported nucleic acid synthesis, specifically where the enzyme is terminal deoxynucleotidyl transferase (TdT) enzyme or modified terminal deoxynucleotidyl transferase (TdT) enzyme.
  • TdT terminal deoxynucleotidyl transferase
  • TdT modified terminal deoxynucleotidyl transferase
  • the invention described herein relates to improved methods of enzymatic solid-supported nucleic acid synthesis where the enzyme is terminal deoxynucleotidyl transferase (TdT) enzyme or modified terminal deoxynucleotidyl transferase (TdT) enzyme.
  • TdT terminal deoxynucleotidyl transferase
  • TdT modified terminal deoxynucleotidyl transferase
  • the inventors have developed surfaces made entirely of polymerized material, rather than coated into a pre-existing support.
  • the term 'made entirely of polymerised material' means that the solid support is not a coated layer on an existing support, but that the solid support is manufactured in its entirety by polymerization.
  • Described herein is a method of nucleic acid synthesis, wherein the method comprises the steps of: (a) providing a solid support made entirely of polymerised material, wherein the polymerised solid support comprises a co-polymer to which an initiator oligonucleotide is attached, wherein the co- polymer is a co-polymer of bisacrylamide and one or more first co-monomer(s) selected from acrylamide, methacrylamide, N-methylacrylamide, N,N'-dimethylacrylamide, N- (hydroxylmethyl)acrylamide, N-(hydroxyethyl)acrylamide, N-[tris(hydroxymethyl)methyl]acrylamide, hydroxyethyl methacrylate and N-vinyl pyrrolidinone and a second co-monomer which attaches to or is attached to the initiator;
  • Described herein is a method of nucleic acid synthesis, wherein the method comprises the steps of:
  • Described herein is a method of nucleic acid synthesis, wherein the method comprises the steps of:
  • the solid support coatings described herein comprise a co-polymer to which an initiator oligonucleotide is attached. Said coatings, when applied to solid supports may create a polymer surface which is effectively immobilised to the solid support.
  • nucleic acid synthesis is carried out at the attached initiator oligonucleotide by addition of a 3'-blocked nucleoside triphosphate in the presence of a terminal deoxynucleotidyl transferase (TdT) enzyme.
  • TdT terminal deoxynucleotidyl transferase
  • the methods described herein are not limited by the format, size, geometry or the material of the solid support itself.
  • the polymeric coatings described herein may be applied to the solid support by any method, including those known in the art. Examples of coatings that may be suited to the methods described herein are described in W02005/065814.
  • the material may be made entirely from polymerised material rather the coated onto an existing solid material.
  • bisacrylamide may be added as an additional component monomer.
  • the solid support can be made of a polymerised mixture of acrylamide, bisacrylamide and an oligonucleotide having one or more double bonds.
  • the blocking group may be cleaved.
  • a method further comprising: (c) cleaving the blocking group from the 3'-blocked nucleoside triphosphate in the presence of a cleaving agent.
  • Cleavage releases a 3' hydroxyl suitable for further addition/extension.
  • the adding step and cleaving steps may be repeated in order to elongate the synthesis product.
  • further nucleotides are added by repeating steps (b) and (c).
  • step (a) comprises the steps of:
  • the first co-monomer has a single reactive point, usually a double bond for polymerisation.
  • the first co-monomer may be one or more of acrylamide, methacrylamide, N-methylacrylamide, N,N'- dimethylacrylamide, hydroxyethyl methacrylate and/or N-vinyl pyrrolidinone.
  • the first co-monomer can be acrylamide.
  • the first co-monomer can be mixture of monomers, including bi-functional monomers such as bisacrylamide which provide cross-linking.
  • the second co-monomer typically contains multiple reactive sites, usually both a double bond and a reactive site suitable for attachment to an initiator oligonucleotide.
  • the reactive moiety can be selected from haloacetamide, carboxylic acid, alkyne, azide, amine or thiol.
  • the second co-monomer can be a haloacetamide-containing monomer.
  • the second co-monomer can be a bromoacetamide- containing monomer.
  • the second co-monomer can contain the initiator oligonucleotide having a suitable double bond.
  • the second co-monomer can be a monomer of formula (4a): wherein R 1 is H or CH 3 ;
  • R 2 is an oligonucleotide or NHCOCH 2 X
  • Y is NR 3 or O; n is 1 to 50;
  • X is Cl, Br, or I
  • R 3 is H or an optionally substituted C 1-5 alkyl group.
  • R 1 can be H.
  • R 2 can be NHCOCH 2 Br.
  • Y can be NH.
  • n can be 5.
  • the second co-monomer can be N-(5-bromoacetamidylpentyl) acrylamide (BRAC).
  • a portion of the second co-monomer can be attached to the initiator.
  • the second co-monomer can comprise an oligonucleotide bearing a 5' methacrylate moiety.
  • the methods described herein are not limited by the format, size, geometry or the material of the solid support itself.
  • the solid support can comprise silica beads, paramagnetic beads, superparamagnetic beads, glass fibres, a glass slide, a plastic well or a plastic slide.
  • the beads can be paramagnetic beads.
  • the beads can be silica beads.
  • the beads can comprise a silica shell.
  • the beads can comprise superparamagnetic cores covered by silica shells.
  • the solid support can be synthesised using the polymerised monomer mixture described herein.
  • the surface coating can be applied as a prepolymerised polymer mixture of the first and second co-monomers.
  • the surface coating can be applied to the solid support during polymerisation of the first and second co-monomers.
  • the pre-polymerisation can be carried out for at least 90 minutes prior to exposure to the surface being coated.
  • the initiator oligonucleotide is attached to the support via a suitable modification to react with the reactive moiety present on the co-polymer.
  • the modification on the initiator oligonucleotide depends on the nature of the reactive moiety present on the co-polymer.
  • the initiator oligonucleotide contains and is coupled via coupled via a phosphorothioate moiety, thus becoming attached via a P-S-CH 2 linkage.
  • click chemistry can be used.
  • the initiator oligonucleotide is coupled via click chemistry between an azide and an alkyne.
  • an amine can be reacted with a carboxyl moiety to form an amide linkage.
  • the initiator oligonucleotide is coupled via amide formation between an amine and a carboxyl moiety.
  • This reaction is typically conducted in the presence of an activating agent such as l-ethyl-3-(3- dimethylaminopropyl)carbodiimide (EDC).
  • EDC l-ethyl-3-(3- dimethylaminopropyl)carbodiimide
  • the oligonucleotide can contain a moiety such as methylacrylate that can be used to attach the oligonucleotide as part of the polymerization process.
  • the initiator can be attached as part of the polymerization process rather than as an additional attachment step after the polymerisation.
  • the initiator sequence can contain a moiety that allows cleavage, such as a non-canonical nucleotide base.
  • the initiator can contain a nucleotide having a base such as uracil or 8-oxo-guanine thereby allowing strand cleavage via exposure to an appropriate glycosylase.
  • Cycles of extension can use a 3'-blocked nucleotide in order to prevent multiple extensions per cycle.
  • the 3'-blocked nucleoside triphosphate can be blocked with a group selected from 3'-O-azidomethyl, 3'-aminooxy, 3'-O-allyl, 3'-O-cyanoethyl, 3'-O-acetyl, 3'-O-nitrate, 3'-O-phosphate, 3'-O-acetyl levulinic ester, 3'-0-tert butyl dimethyl silane, 3'-O-trimethyl(silyl)ethoxymethyl, 3'-O-ortho- nitrobenzyl, or 3'-O-para-nitrobenzyL
  • Suitable enzymes are described below. Any enzyme having template independent polymerase extension activity can be used.
  • a suitable template independent polymerase is terminal deoxynucleotidyl transferase (TdT).
  • the terminal deoxynucleotidyl transferase (TdT) enzyme can be a modified terminal deoxynucleotidyl transferase (TdT) enzyme comprising at least one amino acid modification when compared to a wild type sequence SEQ ID NO 1 or the homologous amino acid sequence of a terminal deoxynucleotidyl transferase (TdT) enzyme in other species.
  • the modification can be selected from one or more of the amino acid regions WLLNRLINRLQNQGILLYYDI, VAIF, EDN, MGA, ENHNQ, FMRA, HAI, TKA, FHS, QADNA, MQK, SAAVCK, EAQA, TVR, KEC, TPEMGK, DHFQ, LAAG, APPVDN, FARHERKMLLDNHA, and YIDP of the sequence of SEQ ID NO 1 or the homologous regions in other species.
  • the cleavage agent depends on the nature of the blocking moiety.
  • the cleaving agent can be tris(2- carboxyethyl)phosphine (TCEP), a palladium complex, an organic or inorganic base, sodium nitrite or a photoactivated transition metal complex.
  • TCEP tris(2- carboxyethyl)phosphine
  • the cleaving agent In order to unblock a 3'-azidomethyl moiety the cleaving agent might be tris(2-carboxyethyl) phosphine (TCEP). In orderto unblock a 3'-aminoxy moiety the cleaving agent might be sodium nitrite. In order to unblock a 3'-al ly I moiety the cleaving agent might be a palladium complex.
  • TCEP tris(2-carboxyethyl) phosphine
  • the cleaving agent In orderto unblock a 3'-aminoxy moiety the cleaving agent might be sodium nitrite. In order to unblock a 3'-al ly I moiety the cleaving agent might be a palladium complex.
  • kits comprising:
  • a solid support wherein the solid support is coated with a co-polymer to which an initiator oligonucleotide is attached, wherein the co-polymer is a co-polymer of a first co-monomer selected from acrylamide, methacrylamide, N-methylacrylamide, N,N'-dimethylacrylamide, hydroxyethyl methacrylate and N-vinyl pyrrolidinone and a second co-monomer which attaches the initiator oligonucleotide;
  • TdT terminal deoxynucleotidyl transferase
  • TdT modified terminal deoxynucleotidyl transferase
  • kits comprising:
  • a solid support wherein the solid support comprises a co-polymer to which an initiator oligonucleotide is attached, wherein the co-polymer is a co-polymer of one or more first comonomer(s) selected from acrylamide, methacrylamide, N-methylacrylamide, N,N'- dimethylacrylamide, N-(hydroxylmethyl)acrylamide, N-(hydroxyethyl)acrylamide, N-
  • TdT terminal deoxynucleotidyl transferase
  • TdT modified terminal deoxynucleotidyl transferase
  • kits comprising:
  • a solid support wherein the solid support comprises a co-polymer to which an initiator oligonucleotide is attached, wherein the co-polymer is a co-polymer of one or more first co- monomers) selected from acrylamide, methacrylamide, N-methylacrylamide, N,N'- dimethylacrylamide, N-(hydroxylmethyl)acrylamide, N-(hydroxyethyl)acrylamide, N-
  • TdT terminal deoxynucleotidyl transferase
  • TdT modified terminal deoxynucleotidyl transferase
  • Described herein is a method of nucleic acid synthesis, wherein the method comprises the steps of:
  • Described herein is a method of nucleic acid synthesis, wherein the method comprises the steps of: (a) providing a solid support, wherein the solid support comprises a co-polymer to which an initiator oligonucleotide is attached, wherein the co-polymer is a co-polymer of one or more first co- monomers) selected from acrylamide, methacrylamide, N-methylacrylamide, N,N'- dimethylacrylamide, N-(hydroxylmethyl)acrylamide, N-(hydroxyethyl)acrylamide, N- [tris(hydroxymethyl)methyl]acrylamide, bisacrylamide, hydroxyethyl methacrylate and N-vinyl pyrrolidinone and a second co-monomer which attaches the initiator; and
  • the method may further comprise the step:
  • nucleotides may be added by repeating steps (b) and (c).
  • step (a) may comprise the steps of:
  • the solid support coatings comprise a co-polymer to which an initiator oligonucleotide is attached. Said coatings, when applied to solid supports may create a polymer surface which is effectively immobilised to the solid support.
  • the coatings comprise a copolymer of one or more first co-monomers and a second co-monomer, wherein the first co-monomer may be selected from acrylamide, methacrylamide, N-methylacrylamide, N,N'-dimethylacrylamide, N- (hydroxylmethyl)acrylamide, N-(hydroxyethyl)acrylamide, N-[tris(hydroxymethyl)methyl]acrylamide, bisacrylamide, hydroxyethyl methacrylate or N-vinyl pyrrolidinone.
  • the first co-monomer may be acrylamide.
  • the second co-monomer serves to provide functionalisation in the form of a chemically reactive group on the support such that the resultant co-polymer allows coupling of the co-polymer to an initiator oligonucleotide, thereby immobilizing the initiator oligonucleotide.
  • the second co-monomer can be selected from any co-monomer that is suitable for allowing coupling of the resultant co-polymer to an initiator oligonucleotide.
  • the second co-monomer can for example be selected from a thiol- containing monomer, an amine-containing monomer, an acid-containing monomer, a haloacetamide- containing monomer, an alkyne-containing monomer and an azide-containing monomer.
  • the second co-monomer can be a haloacetamide-containing monomer.
  • the second co-monomer can be a bromoacetamide-containing monomer.
  • the second co-monomer can be /V-(5- bromoacetamidylpentyl) acrylamide (BRAC).
  • the second co-monomer may contain a reactive moiety selected from haloacetamide, carboxylic acid, alkyne, azide, amine or thiol.
  • the second co-monomer can be a monomer of formula (1a) or (1b): (1b); wherein Q. is any group suitable to allow coupling of the resultant co-polymer to an initiator oligonucleotide; and V is a linker group.
  • Q can be attached to the initiator oligonucleotide, for example in the form of a methacrylate group.
  • Q can be a group suitable to allow coupling of the resultant co-polymer to an initiator oligonucleotide.
  • Q can be a group comprising an azide, haloacetamide, alkyne, amine, carboxylic acid or thiol moiety.
  • Q can be a group comprising a haloacetamide moiety.
  • Q can be NHC(O)CH 2 Br.
  • V can be any suitable linker group.
  • V can be selected from an optionally substituted alkyl linker, an optionally substituted alkoxy linker or an optionally substituted polyethylene glycol linker.
  • V can be optionally substituted C 1-50 alkyl.
  • V can be optionally substituted C(0)C 1-50 alkyl.
  • V can be -(OCH 2 CH 2 )-n where n is 1 to 20.
  • the second co-monomer can be a monomer of formula (2a) or (2b): wherein Q is any group suitable to allow coupling of the resultant co-polymer to an initiator oligonucleotide;
  • Y is NR 1 or O
  • Z is an optionally substituted C 1-50 alkyl bridge; and R 1 is H or an optionally substituted C 1-5 alkyl group.
  • Q can be attached to the initiator oligonucleotide, for example in the form of a methacrylate group.
  • Q can be a group suitable to allow coupling of the resultant co-polymer to an initiator oligonucleotide.
  • Q. can be a group comprising an azide, haloacetamide, alkyne, amine, carboxylic acid or thiol moiety.
  • Cl ean be a group comprising a haloacetamide moiety.
  • Q can be NHC(O)CH 2 Br.
  • V can be any suitable linker group.
  • V can be selected from an optionally substituted alkyl linker, an optionally substituted alkoxy linker or an optionally substituted polyethylene glycol linker.
  • V can be optionally substituted C 1-50 alkyl.
  • V can be optionally substituted C(O)C 1-50 alkyl.
  • V can be -(OCH 2 CH 2 )-n where n is 1 to 20.
  • Y can be NH. Y can be 0.
  • R 1 can be H.
  • R 1 can be an optionally substituted C 1-5 alkyl group.
  • Z can be an optionally substituted C 1-20 alkyl bridge.
  • Z can be an optionally substituted C 1-10 alkyl bridge.
  • Z can be an optionally substituted C 5 alkyl bridge.
  • Z can be a C 5 alkyl bridge.
  • the second co-monomer can be a monomer of formula (3) or (3a): wherein X is Cl, Br or I;
  • Y is NR 1 or O
  • Z is an optionally substituted C 1-50 alkyl bridge; and R 1 is H or an optionally substituted C 1-5 alkyl group.
  • X can be Br.
  • X can be Cl.
  • X can be I.
  • Y can be NH.
  • Y can be O.
  • R 1 can be H.
  • R 1 can be an optionally substituted C 1-5 alkyl group.
  • Z can be an optionally substituted C 1-20 alkyl bridge.
  • Z can be an optionally substituted C 1-10 alkyl bridge.
  • Z can be an optionally substituted C 5 alkyl bridge.
  • Z can be a C 5 alkyl bridge.
  • the second co-monomer can be a monomer of formula (4) or (4a): wherein X is Cl, Br or I;
  • Y is NR 1 or O; n is 1 to 50; and R 1 is H or an optionally substituted C 1-5 alkyl group.
  • X can be Br.
  • X can be Cl.
  • X can be I.
  • Y can be NH.
  • Y can be 0.
  • R 1 can be H.
  • R 1 can be an optionally substituted C 1-5 alkyl group, n can be 2 to 10. n can be 5.
  • the polymerisation reaction between the first and second comonomer may be carried out in the presence or absence of the solid support.
  • the coating is applied to the solid support as the polymerisation reaction progresses. Accordingly the coating may be applied to the solid support during polymerisation of the first and second co-monomers.
  • the polymerisation reaction may be carried out independently of the solid support. Therefore the resultant co-polymer may be coated on to the solid support separately to the polymerisation process. Accordingly the coating may be applied to the solid support as a pre-polymerised polymer mixture of the first and second co-monomers.
  • the first co-monomer is used in a molar excess relative to the second co-monomer.
  • the second co-monomer may be present in an amount of 1 mol% or less relative to the total molar quantity of co-monomers.
  • the second co-monomer may be present in an amount of 1 mol% or greater relative to the total molar quantity of co-monomers.
  • the second co-monomer may be present in an amount of 2 mol% or greater relative to the total molar quantity of co-monomers.
  • the initiator oligonucleotide is coupled to the solid support co-polymer coating to form a solid-supported initiator oligonucleotide.
  • the initiator oligonucleotide may be coupled to the solid support co-polymer coating using any suitable method.
  • the initiator oligonucleotide may for example be coupled to the solid support co-polymer coating via a phosphorothioate moiety or via click chemistry between an azide and an alkyne.
  • the initiator oligonucleotide is coupled via a phosphorothioate moiety.
  • the second co-monomer is a haloacetamide-containing monomer and the initiator oligonucleotide is coupled to the solid support co-polymer coating via a phosphorothioate moiety, wherein the phosphorothioate moiety couples to the co-polymer by displacement of halide from the haloacetamide-containing portion of the co-polymer.
  • the initiator oligonucleotide Prior to coupling to the solid support co-polymer coating the initiator oligonucleotide may comprise a moiety of formula (5): wherein, U is O, S or NR 2 ;
  • T is O, S or an optionally substituted C 1-10 alkyl group
  • W is 0 or S
  • R 2 is H or an optionally substituted C 1-10 alkyl group.
  • the initiator oligonucleotide may comprise a moiety of formula:
  • the phosphorothioate can be on the terminus of the oligonucleotide, as shown above, or can be internal to the sequence. Coupling can be performed using a moiety of formula: where Ri is an oligo fragment and Rj is an oligo fragment.
  • the methods described herein are not limited by the format, size, geometry or the material of the solid support itself.
  • the solid support may comprise any material suited to the methods of the invention.
  • the solid support may be a silica based solid support.
  • the solid support may be a silica based solid support wherein said silica is fused silica.
  • the solid support may be a polystyrene based support.
  • the solid support may be a plastic well or a plastic slide.
  • the solid support may comprise silica beads, magnetic beads, paramagnetic beads, superparamagnetic beads, glass fibres or a glass slide.
  • the solid support may be silica beads.
  • the solid support may be silica superparamagnetic beads.
  • the solid support may be polystyrene beads.
  • the solid support may be a non-silica based support.
  • the solid support may comprise silica beads, paramagnetic beads, glass fibres, a glass slide, a plastic well or a plastic slide.
  • the beads may be silica beads or comprise a silica shell. Alternatively the material may be made entirely from polymerised material rather than coated onto an existing solid material.
  • the solid support particles may have a diameter within the range of 0.1-200 ⁇ m.
  • the solid support particles may have a diameter within the range of 0.1-50 ⁇ m.
  • the solid support particles may have a diameter within the range of 100-5000 nm.
  • the nucleic acid strands may include a cleavage site to enable cleavage from the solid support.
  • the cleavage site may be a base or base sequence recognisable by an enzyme.
  • a base recognised by an enzyme, such as a glycosylase, may be removed to generate an abasic site which may be cleaved by chemical or enzymatic means.
  • An example of such a glycosylase system includes the presence of a uracil base in the initiator sequence, which may be excised with uracil DNA glycosylase (UDG) to leave an abasic site which may be cleaved with, for example, basic solutions, organic amines, or an endonuclease (such as endonuclease VIII), to release a nucleic acid bearing a 5'-phosphate into solution.
  • UDG uracil DNA glycosylase
  • a base sequence may be recognised and cleaved by a restriction enzyme.
  • 3'-blocked nucleoside triphosphates are added in the presence of a terminal deoxynucleotidyl transferase (TdT) enzyme which results in extension of the solid-supported sequence by one nucleotide unit.
  • TdT terminal deoxynucleotidyl transferase
  • the 3'-blocking group present on the 3'-blocked nucleoside triphosphates prevents further incorporation of nucleotides.
  • the solid-supported nucleotide sequence may be further extended by adding a further 3'-blocked nucleoside triphosphate in the presence of a terminal deoxynucleotidyl transferase (TdT) enzyme.
  • Cleavage of the blocking group and addition of a further 3'-blocked nucleoside triphosphate in the presence of a terminal deoxynucleotidyl transferase (TdT) enzyme may be repeated any number of times as desired to synthesise a target sequence.
  • the 3'-blocked nucleoside 5'-triphosphate can be blocked by any chemical group that can be unmasked to reveal a 3'-OH.
  • the 3'-blocked nucleoside triphosphate can be blocked by a 3'-O-azidomethyl, 3'-aminooxy, 3'-O-allyl group, 3'-O-cyanoethyl, 3'-O-acetyl, 3'-O-nitrate, 3'-O- phosphate, 3'-O-acetyl levulinic ester, 3'-0-tert butyl dimethyl silane, 3'-O-aminoxy oxime, 3'-O- trimethyl(silyl)ethoxymethyl, 3'-O-ortho-nitrobenzyl, and 3'-O-para-nitrobenzyl.
  • the 3'-blocking group may be selected from 3'-O-azidomethyl, 3'-aminooxy, 3'-O-cyanoethyl and a 3'-O-allyl group.
  • the 3'-blocked nucleoside 5'-triphosphate can also be blocked by any chemical group that can be directly utilized in chemical ligations, such as copper-catalyzed or copper-free azide-alkyne click reactions and tetrazine-alkene click reactions.
  • the 3'-blocked nucleoside triphosphate can include chemical moieties containing an azide, alkyne, alkene, and tetrazine.
  • the 3'- blocked nucleoside 5'-triphosphate can be blocked by a chemical group that can be unmasked to reveal a 3'-O-NH2, which can subsequently be unmasked to reveal a 3'-OH.
  • the 3'-blocked nucleoside triphosphate can be blocked by a 3'-O-NC(CH 3 ) 2 -
  • the blocking group of the 3'-blocked nucleoside triphosphate is cleaved in the presence of a cleaving agent.
  • the cleaving agent used will depend on the 3'-blocking group present and may be any cleaving agent suitable for cleaving the 3'-blocking group.
  • tris(2-carboxyethyl)phosphine (TCEP) or tris(hydroxypropyl)phosphine (THPP) can be used to cleave a 3'-O-azidomethyl group
  • palladium complexes can be used to cleave a 3'-O-allyl group
  • sodium nitrite can be used to cleave a 3'-aminoxy group.
  • the cleaving agent is selected from: tris(2- carboxyethyl)phosphine (TCEP), a palladium complex or sodium nitrite.
  • the cleaving agent may be selected from tris(2-carboxyethyl)phosphine (TCEP), tris(hydroxypropyl)phosphine (THPP), a palladium complex, an organic or inorganic base, sodium nitrite and a photoactivated transition metal complex.
  • TCEP tris(2-carboxyethyl)phosphine
  • THPP tris(hydroxypropyl)phosphine
  • a palladium complex an organic or inorganic base
  • sodium nitrite sodium nitrite
  • the photoactivated transition metal complex is tris(2,2'- bipyridyl)ruthenium(ll)).
  • the cleaving agent is added in the presence of a cleavage solution comprising a denaturant, such as urea, guanidinium chloride, formamide or betaine.
  • a denaturant such as urea, guanidinium chloride, formamide or betaine.
  • the cleavage solution comprises one or more buffers. It will be understood by the person skilled in the art that the choice of buffer is dependent on the exact cleavage chemistry and cleaving agent required.
  • TdT terminal deoxynucleotidyl transferase
  • TdT modified terminal deoxynucleotidyl transferase
  • Sequences described herein are modified from the sequence of the Spotted Gar, but the corresponding changes can be introduced into the homologous sequences from other species. Terminal transferases are ubiquitous in nature and are present in many species. Many known TdT sequences have been reported in the NCBI database http://www.ncbi.nlm, nih.gov/. The inventors have identified a number of modified TdT enzymes with improved properties. Any such TdT enzyme or modified TdT enzyme or a truncated version thereof may be used in the methods described herein.
  • the inventors have modified the terminal transferase from Lepisosteus oculatus TdT (spotted gar) (shown below). However the corresponding modifications can be introduced into the analogous terminal transferase sequences from any other species, including the sequences listed above in the various NCBI entries.
  • the amino acid sequence of the spotted gar (Lepisosteus oculatus) is shown below (SEQ ID NO: 1)
  • the inventors have identified various regions in the amino acid sequence having improved properties. Certain regions improve the solubility and handling of the enzyme. Certain other regions improve the ability to incorporate nucleotides with modifications at the 3'-position.
  • Modifications which improve the solubility include a modification within the amino acid region WLLNRLINRLQNQGILLYYDIV shown highlighted in the sequence below.
  • Modifications which improve the incorporation of modified nucleotides can be at one or more of selected regions shown below.
  • the second modification can be selected from one or more of the amino acid regions VAIF, EDN, MGA, ENHNQ, FMRA, HAI, TKA, FHS, QADNA, MQK, SAAVCK, EAQA, TVR, KEC, TPEMGK, DHFQ, LAAG, APPVDN, FARHERKMLLDNHA, and YIDP shown highlighted in the sequence below.
  • Modified terminal deoxynucleotidyl transferase (TdT) enzymes comprising at least one amino acid modification when compared to a wild type sequence SEQ ID NO 1 or the homologous amino acid sequence of a terminal deoxynucleotidyl transferase (TdT) enzyme in other species may be preferable for use in the methods described herein, wherein the modification is selected from one or more of the amino acid regions WLLNRLINRLQNQGILLYYDI, VAIF, EDN, MGA, ENHNQ, FMRA, HAI, TKA, FHS, QADNA, MQK, SAAVCK, EAQA, TVR, KEC, TPEMGK, DHFQ, LAAG, APPVDN, FARHERKMLLDNHA, and YIDP of the sequence of SEQ ID NO 1 or the homologous regions in other species.
  • Homologous refers to protein sequences between two or more proteins that possess a common evolutionary origin, including proteins from superfamilies in the same species of organism as well as homologous proteins from different species. Such proteins (and their encoding nucleic acids) have sequence homology, as reflected by their sequence similarity, whether in terms of percent identity or by the presence of specific residues or motifs and conserved positions.
  • a variety of protein (and their encoding nucleic acid) sequence alignment tools may be used to determine sequence homology. For example, the Clustal Omega multiple sequence alignment program provided by the European Molecular Biology Laboratory (EMBL) can be used to determine sequence homology or homologous regions. Preferable sequences can contain both modifications, namely a.
  • a first modification is within the amino acid region WLLNRLINRLQNQGILLYYDI of the sequence of SEQ ID NO 1 or the homologous region in other species; and b. a second modification is selected from one or more of the amino acid regions VAIF, EDN, MGA, ENHNQ, FMRA, HAI, TKA, FHS, QADNA, MQK, SAAVCK, EAQA, TVR, KEC, TPEMGK, DHFQ, LAAG, APPVDN, FARHERKMLLDNHA, and YIDP of the sequence of SEQ ID NO 1 or the homologous regions in other species.
  • Bos taurus (bovine) TdT As a comparison with other species, the sequence of Bos taurus (bovine) TdT is shown below (SEQ ID NO: 2):
  • Modifications which improve the solubility include a modification within the amino acid region QLLPKVINLWEKKGLLLYYDLV shown highlighted in the sequence below.
  • Modifications which improve the incorporation of modified nucleotides can be at one or more of selected regions shown below.
  • the second modification can be selected from one or more of the amino acid regions LVLF, ENN, MGA, NNYNH, FMRA, FTI, VKC, FRS, MSDKT, MQK, EAEA, AVW, KKI, SPGSAE, DHFQ, MCPYEN, YATHERKMMLDNHA, and YIEP shown highlighted in the sequence below.
  • Modifications which improve the solubility include a modification within the amino acid region QLLHKVTDFWKQQGLLLYCDIL shown highlighted in the sequence below: Modifications which improve the incorporation of modified nucleotides can be at one or more of selected regions shown below.
  • the second modification can be selected from one or more of the amino acid regions LVLF, ENN, MGA, NNYNQ, FMRA, FPL VKS, FRT, QSDKS, MQK, VSCVNR, EAEA, AVV, KMT, SPEATE, DHFQ, MCPYDR, YATHERKMMLDNHA, and YIEP shown highlighted in the sequence below.
  • Modified terminal deoxynucleotidyl transferase (TdT) enzymes that may be used in the methods of the invention may comprise at least one amino acid modification when compared to a wild type sequence SEQ ID NO 1 or the homologous amino acid sequence of a terminal deoxynucleotidyl transferase (TdT) enzyme in other species, wherein the modification is selected from one or more of the amino acid regions WLLNRLINRLQNQGILLYYDI, VAIF, EDN, MGA, ENHNQ, FMRA, HAI, TKA, FHS, QADNA, MQK, SAAVCK, EAQA, TVR, KEC, TPEMGK, DHFQ, LAAG, APPVDN, FARHERKMLLDNHA, and YIDP of the sequence of SEQ ID NO 1 or the homologous regions in other species.
  • TdT enzymes that may be used in the methods of the invention include a modified TdT enzyme comprising at least two amino acid modifications when compared to a wild type sequence SEQ ID NO 1 or the homologous amino acid sequence of a terminal deoxynucleotidyl transferase (TdT) enzyme in other species, wherein; a. a first modification is within the amino acid region WLLNRLINRLQNQGILLYYDIV of the sequence of SEQ ID NO 1 or the homologous region in other species; and b.
  • a second modification is selected from one or more of the amino acid regions VAIF, EDN, MGA, ENHNQ, FMRA, HAI, TKA, FHS, QADNA, MQK, SAAVCK, EAQA, TVR, KEC, TPEMGK, DHFQ, LAAG, APPVDN, FARHERKMLLDNHA, and YIDP of the sequence of SEQ ID NO 1 or the homologous regions in other species.
  • a first modification is within the amino acid region QLLPKVINLWEKKGLLLYYDLV of the sequence of SEQ ID NO 2 or the homologous region in other species; and b. a second modification is selected from one or more of the amino acid regions LVLF, ENN, MGA, NNYNH, FMRA, FTI, VKC, FRS, MSDKT, MQK, EAEA, AVW, KKI, SPGSAE, MCP, YATHERKMMLDNHA, and YIEP of the sequence of SEQ ID NO 2 or the homologous regions in other species.
  • a first modification is within the amino acid region QLLHKVTDFWKQQGLLLYCDIL of the sequence of SEQ ID NO 3 or the homologous region in other species; and b. a second modification is selected from one or more of the amino acid regions LVLF, ENN, MGA, NNYNQ, FMRA, FPI, VKS, FRT, QSDKS, MQK, VSCVNR, EAEA, AVV, KMT, SPEATE, DHFQ, MCPYDR, YATHERKMMLDNHA, and YIEP of the sequence of SEQ ID NO 3 or the homologous regions in other species.
  • the modifications can be chosen from any amino acid that differs from the wild type sequence.
  • the amino acid can be a naturally occurring amino acid.
  • the modified amino acid can be selected from ala, arg, asn, asp, cys, gin, glu, gly, his, ile, leu, lys, met, phe, pro, ser, thr, trp, val, and sec.
  • sequences can be modified at positions in addition to those regions described.
  • Embodiments of the invention may include for example methods that make use of sequences having modifications to amino acids outside the defined positions, providing those sequences retain terminal transferase activity.
  • Embodiments of the invention may include for example methods that make use of sequences having truncations of amino acids outside the defined positions, providing those sequences retain terminal transferase activity.
  • the sequences may be BRCT truncated as described in application WQ2018215803 where amino acids are removed from the N-terminus whilst retaining or improving activity. [ Alterations, additions, insertions or deletions or truncations to amino acid positions are therefore within the scope of the methods of the invention.
  • the modification within the region WLLNRLINRLQNQGILLYYDIV or the corresponding region from other species help improve the solubility of the enzyme.
  • the modification within the amino acid region WLLNRLINRLQNQGILLYYDIV can be at one or more of the underlined amino acids.
  • Particular changes can be selected from W-Q, N-P, R-K, L-V, R-L, L-W, Q-E, N-K, Q-K or l-L.
  • the sequence WLLNRLINRLQNQGILLYYDIV can be altered to QLLPKVINLWEKKGLLLYYDLV.
  • the second modification improves incorporation of nucleotides having a modification at the 3' position in comparison to the wild type sequence.
  • the second modification can be selected from one or more of the amino acid regions VAIF, EDN, MGA, ENHNQ, FMRA, HAI, TKA, FHS, QADNA, MQK, SAAVCK, EAQA, TVR, KEC, TPEMGK, DHFQ, LAAG, APPVDN, FARHERKMLLDNHA, and YIDP of the sequence of SEQ ID NO 1 or the homologous regions in other species.
  • the second modification can be selected from two or more of the amino acid regions VAIF, EDN, MGA, ENHNQ, FMRA, HAI, TKA, FHS, QADNA, MQK, SAAVCK, EAQA, TVR, KEC, TPEMGK, DHFQ, LAAG, APPVDN, FARHERKMLLDNHA, and YIDP of the sequence of SEQ ID NO 1 or the homologous regions in other species shown highlighted in the sequence below.
  • the identified positions commence at positions V32, E74, M108, F182, T212, D271, M279, E298, A421, L456, Y486.
  • Modifications disclosed herein contain at least one modification at the defined positions.
  • the modified amino acid can be in the region FMRA.
  • the modified amino acid can be in the region QADNA.
  • the modified amino acid can be in the region EAQA.
  • the modified amino acid can be in the region APP.
  • the modified amino acid can be in the region LDNHA.
  • the modified amino acid can be in the region YIDP.
  • the region FARHERKMLLDNHA is advantageous for removing substrate biases in modifications.
  • the FARHERKMLLDNHA region appears highly conserved across species.
  • the modification selected from one or more of the amino acid regions FMRA, QADNA, EAQA, APP, FARHERKMLLDNHA, and YIDP can be at the underlined amino acid(s).
  • the positions for modification can include A53, V68, V71, D75, E97, 1101, G109, Q115, V116, S125, T137, Q143, N154, H155, Q157, 1158, 1165, G177, L180, A181, M183, A195, K200, T212, K213, A214, E217, T239, F262, 5264, Q269, N272, A273, K281, S291, K296, Q300, T309, R311, E330, T341, E343, G345, N352, N360, Q361, 1363, Y367, H389, L403, G406, D411, A421, P422, V424, N426, R438, F447, R452, L455, and/or D488.
  • Amino acid changes include any one of A53G, V68I, V71I, D75N, D75Q, E97A, 1101V, G109E, G109R, Q115E, V116I, V116S, S125R, T137A, Q143P, N154H, H155C, Q157K, Q157R, I158M, 1165V, G177D, L180V, A181E, M183R, A195P, K200R, T212S, K213S, A214R, E217Q, T239S, F262L, S264T, Q269K, N272K, A273S, A273T, K281R, S291N, K296R, Q300D, T309A, R311W, E330N, T341S, E343Q, G345R, N352Q, N360K, Q361K, I363L, Y367C, H389A, L403R, G
  • Amino acid changes include any two or more of A53G, V68I, V71I, D75N, D75Q, E97A, 1101V, G109E, G109R, Q115E, V116I, V116S, S125R, T137A, Q143P, N154H, H155C, Q157K, Q157R, I158M, 1165V, G177D, L180V, A181E, M183R, A195P, K200R, T212S, K213S, A214R, E217Q, T239S, F262L, S264T, Q269K, N272K, A273S, A273T, K281R, S291N, K296R, Q300D, T309A, R311W, E330N, T341S, E343Q, G345R, N352Q, N360K, Q361K, I363L, Y367C, H389A, L403R
  • the modification of QADNA to KADKA, QADKA, KADNA, QADNS, KADNT, or QADNT is advantageous for the incorporation of 3'-O-modified nucleoside triphosphates to the 3'-end of nucleic acids and removing substrate biases during the incorporation of modified nucleoside triphosphates.
  • the modification of APPVDN to MCPVDN, MPPVDN, ACPVDR, VPPVDN, LPPVDR, ACPYDN, LCPVDN, or MAPVDN is advantageous for the incorporation of 3'-O-modified nucleoside triphosphates to the 3'- end of nucleic acids and removing substrate biases during the incorporation of modified nucleoside triphosphates.
  • FARHERKMLLDRHA WARHERKMILDNHA, FARHERKMILDNHA, WARHERKMLLDNHA, FARHERKMLLDRHA, or FARHEKKMLLDNHA is also advantageous for the incorporation of 3'-O-modifiecl nucleoside triphosphates to the 3'-end of nucleic acids and removing substrate biases during the incorporation of modified nucleoside triphosphates.
  • the modification can be selected from one or more of the following sequences FRRA, QADKA, EADA, MPP, FARHERKMLLDRHA, and YIPP. Included is a modified terminal deoxynucleotidyl transferase (TdT) enzyme wherein the second modification is selected from two or more of the following sequences FRRA, QADKA, EADA, MPP, FARHERKMLLDRHA, and YIPP. Included is a modified terminal deoxynucleotidyl transferase (TdT) enzyme wherein the second modification contains each of the following sequences FRRA, QADKA, EADA, MPP, FARHERKMLLDRHA, and YIPP.
  • nucleoside triphosphates refer to a molecule containing a nucleoside (i.e. a base attached to a deoxyribose or ribose sugar molecule) bound to three phosphate groups.
  • nucleoside triphosphates that contain deoxyribose are: deoxyadenosine triphosphate (dATP), deoxyguanosine triphosphate (dGTP), deoxycytidine triphosphate (dCTP) or deoxythymidine triphosphate (dTTP).
  • nucleoside triphosphates examples include adenosine triphosphate (ATP), guanosine triphosphate (GTP), cytidine triphosphate (CTP) or uridine triphosphate (UTP).
  • ATP adenosine triphosphate
  • GTP guanosine triphosphate
  • CTP cytidine triphosphate
  • UDP uridine triphosphate
  • Other types of nucleosides may be bound to three phosphates to form nucleoside triphosphates, such as naturally occurring modified nucleosides and artificial nucleosides.
  • references herein to '3'-blocked nucleoside triphosphates' refer to nucleoside triphosphates (e.g., dATP, dGTP, dCTP or dTTP) which have an additional group on the 3' end which prevents further addition of nucleotides, i.e., by replacing the 3'-OH group with a protecting group.
  • nucleoside triphosphates e.g., dATP, dGTP, dCTP or dTTP
  • references herein to '3'-block', '3'-blocking group' or '3'-protecting group' refer to the group attached to the 3' end of the nucleoside triphosphate which prevents further nucleotide addition.
  • the present method uses reversible 3'-blocking groups which can be removed by cleavage to allow the addition of further nucleotides.
  • irreversible 3'-blocking groups refer to dNTPs where the 3'-OH group can neither be exposed nor uncovered by cleavage.
  • references herein to 'cleaving agent' referto a substance which is able to cleave the 3'- blocking group from the 3'-blocked nucleoside triphosphate.
  • the cleaving agent is a chemical cleaving agent.
  • the cleaving agent is an enzymatic cleaving agent.
  • References herein to an 'initiator oligonucleotide' refer to a short oligonucleotide with a free 3'-end which the 3'-blocked nucleoside triphosphate can be attached to.
  • the initiator sequence is a DNA initiator sequence. In an alternative embodiment, the initiator sequence is an RNA initiator sequence.
  • references herein to a 'DNA initiator sequence' refer to a short DNA oligonuleotide with a free 3'-end which the 3'-blocked nucleoside triphosphate can be attached to, i.e., DNA will be synthesised from the end of the DNA initiator sequence.
  • the initiator oligonucleotide is between 5 and 50 nucleotides long, such as between 5 and 30 nucleotides long (i.e. between 10 and 30), in particular between 5 and 20 nucleotides long (i.e., approximately 20 nucleotides long), more particularly 5 to 15 nucleotides long, for example 10 to 15 nucleotides long, especially 12 nucleotides long.
  • the initiator oligonucleotide is single-stranded. In an alternative embodiment, the initiator oligonucleotide is double-stranded. It will be understood by persons skilled in the art that a 3'-overhang (I.e., a free 3'-end) allows for efficient addition.
  • the initiator oligonucleotide is immobilised on a solid support. This allows TdT and the cleaving agent to be removed between cycles of sequence extension without washing away the synthesised nucleic acid.
  • the methods described herein may be carried out under aqueous conditions so that the methods can be easily performed via a flow setup.
  • the terminal deoxynucleotidyl transferase is added in the presence of an extension solution comprising one or more buffers (e.g., Tris or cacodylate), one or more salts (e.g., Na + , K + , Mg 2+ , Mn 2+ , Cu 2+ , Zn 2+ , Co 2+ , etc. all with appropriate counterions, such as Cl) and inorganic pyrophosphatase (e.g., the Saccharomyces cerevisiae or Escherichia coli homolog).
  • buffers e.g., Tris or cacodylate
  • salts e.g., Na + , K + , Mg 2+ , Mn 2+ , Cu 2+ , Zn 2+ , Co 2+ , etc. all with appropriate counterions, such as Cl
  • inorganic pyrophosphatase e.g., the Saccharomyces cerevisiae or Escherichia
  • step (b) is performed at a pH range between 5 and 10. Therefore, it will be understood that any buffer with a buffering range of pH 5-10 could be used, for example cacodylate, Tris, HEPES or Tricine, in particular cacodylate or Tris.
  • step (c) is performed at a temperature less than 99 °C, such as less than 95 °C, 90 °C, 85 °C, 80 °C, 75 °C, 70 °C, 65 °C, 60 °C, 55 °C, 50 °C, 45 °C, 40 °C, 35 °C, or 30 °C.
  • a temperature less than 99 °C, such as less than 95 °C, 90 °C, 85 °C, 80 °C, 75 °C, 70 °C, 65 °C, 60 °C, 55 °C, 50 °C, 45 °C, 40 °C, 35 °C, or 30 °C.
  • the optimal temperature will depend on the cleavage agent utilised. The temperature used helps to assist cleavage and disrupt any secondary structures formed during nucleotide addition.
  • wash solution comprises the same buffers and salts as used in the extension solution described herein. This has the advantage of allowing the wash solution to be collected and recycled as extension solution in step (b) when the method steps are repeated.
  • the wash solution contains agents to abolish secondary structure or protein- nucleic acid interactions.
  • agents are known in the art to include monovalent salts, divalent salts, chaotropic agents such as guanidinium chloride, proteinase K, detergents, and surfactants.
  • kit suitable for carrying out the methods of the invention, wherein the kit comprises:
  • a solid support wherein the solid support is coated with a co-polymer to which an initiator oligonucleotide is attached, wherein the co-polymer is a co-polymer of a first co-monomer selected from acrylamide, methacrylamide, N-methylacrylamide, N,N'-dimethylacrylamide, hydroxyethyl methacrylate and N-vinyl pyrrolidinone and a second co-monomer which attaches the initiator oligonucleotide;
  • TdT terminal deoxynucleotidyl transferase
  • TdT modified terminal deoxynucleotidyl transferase
  • kits comprising:
  • a solid support comprising a co-polymer to which an initiator oligonucleotide is attached, wherein the co-polymer is a co-polymer of one or more first comonomers) selected from acrylamide, methacrylamide, N-methylacrylamide, N,N'- dimethylacrylamide, N-(hydroxylmethyl)acrylamide, N-(hydroxyethyl)acrylamide, N- [tris(hydroxymethyl)methyl]acrylamide, hydroxyethyl methacrylate and N-vinyl pyrrolidinone and a second co-monomer which attaches the initiator;
  • first comonomers selected from acrylamide, methacrylamide, N-methylacrylamide, N,N'- dimethylacrylamide, N-(hydroxylmethyl)acrylamide, N-(hydroxyethyl)acrylamide, N- [tris(hydroxymethyl)methyl]acrylamide, hydroxyethyl methacrylate and N-vinyl pyrrolidinone and a
  • TdT terminal deoxynucleotidyl transferase
  • TdT modified terminal deoxynucleotidyl transferase
  • the method can be performed on a microfluidic device such as a digital microfluidic device.
  • Digital microfluidics refers to a two-dimensional planar surface platform for lab-on-a-chip systems that is based upon the manipulation of microdroplets. Droplets can be dispensed, moved, stored, mixed, reacted, or analyzed on a platform with a set of insulated electrodes. Digital microfluidics can be used together with analytical analysis procedures such as mass spectrometry, colorimetry, electrochemical, and electrochemiluminescense.
  • the droplet can be moved using any means of electrokinesis.
  • the aqueous droplet can be moved using electrowetting-on-dielectric (EWoD).
  • EWOD electrowetting on a dielectric
  • EWOD Electrowetting on a dielectric
  • a droplet of a conducting liquid is placed on a dielectric layer with insulating and hydrophobic properties.
  • the dielectric layer becomes less hydrophobic, thus causing the droplet to spread onto the surface.
  • the electrical signal on the EWoD or optically-activated amorphous silicon (a-Si) EWoD device can be delivered through segmented electrodes, active-matrix thin-film transistors or digital micromirrors.
  • Optically-activated s-Si EWoD devices are well known in the art for actuating droplets (J. Adhes. Sci. Technol., 2012, 26, 1747-1771).
  • the oil in the device can be any water immiscible or hydrophobic liquid.
  • the oil can be mineral oil, silicone oil, an alkyl-based solvent such as decane or dodecane, or a fluorinated oil.
  • the air in the device can be any humidified gas.
  • the droplets can be actuated on a hydrophobic surface on the digital microfluidic device (ACS Nano 2018, 12, 6, 6050-6058).
  • the hydrophobic surface can be a hydrophobic surface such as polytetrafluoroethylene (PTFE), Teflon AF (DuPont Inc), CYTOP (AGC Chemicals Inc), or FluoroPel (Cytonix LLC).
  • PTFE polytetrafluoroethylene
  • Teflon AF DuPont Inc
  • CYTOP APC Chemicals Inc
  • FluoroPel Cytonix LLC
  • the hydrophobic surface may be modified in such a way to reduce biofouling, especially biofouling resulting from exposure to CFPS reagents or nucleic acid reagents.
  • the hydrophobic surface may also be superhydrophobic, such as NeverWet (NeverWet LLC) or Ultra-Ever Dry (Flotech Performance Systems Ltd).
  • the hydrophobic surface can also be a slippery liquid infused porous surface (SLIPS), which can be formed by infusing Krtox-103 oil (DuPont) with porous PTFE film (Lab Chip, 2019, 19, 2275).
  • SLIPS slippery liquid infused porous surface
  • Silica magbeads were subjected to a series of coating treatments with the same PAC-BRAC polymer formulation to determine whether the coating time, or the period of pre-polymerisation prior to coating, affected the following set of factors:
  • Magnetic particles Silica-coated 1 ⁇ m magnetic particles (Alpha Nanotech, 50 mg/mL suspension) were used for all of the conditions described.
  • Particle washing 7 mg (140 ⁇ L) of silica-coated 1 ⁇ m magnetic particles (Si-beads) were washed prior to PAC-BRAC polymer coating by sequentially washing in Decon90, milliQ water, NaOH, HCI, and milliQ. water.
  • PAC-BRAC polymerisation The PAC-BRAC polymer solution used to coat the washed Si-beads was prepared as follows. 10 mL of 0.8% acrylamide solution (Sigma PN: A4058-100ML) was degassed before addition of 165 ⁇ l 10% BRAC (N-(5-bromoacetamidylpentyl)acrylamide) in DMF. To this solution was added 11.5 ⁇ l TEMED (Sigma PN: T9281-25ML). Polymerisation was initiated by addition of 100 ⁇ l 5% potassium persulfate solution (Sigma PN: 216224). Solution was left to stand at RT until required for coating.
  • BRAC N-(5-bromoacetamidylpentyl)acrylamide
  • Si-bead coating with PAC-BRAC polymer solution The MilliQ supernatant was removed and discarded from Si-beads. Si-beads were coated with PAC-BRAC polymer solution as outlined in Table 1. 167 p.L aliquots of PAC-BRAC solution were used to resuspend each of the pellets, either immediately after PAC-BRAC polymerisation initiation (tO) or after a delay following initiation as shown in Table 1.
  • U UDG-cleavable 2d
  • U base Washing of oligo-PAC-BRAC-Si-beads Each aliquot of oligo-PAC-BRAC-Si-beads was washed with a high salt buffer. Washed pellets were resuspended in 50% formamide/milliQ water and the suspension incubated at 37 °C for 30 minutes. After formamide treatment, oligo-immobilized bead aliquots were washed with a high salt buffer and finally resuspended in HEPES-KOH pH 7.2 ready for use in enzymatic synthesis reactions.
  • N+l enzymatic synthesis reactions Enzymatic 3'-oxyamine N+l nucleotide addition reactions were conducted on each of the oligo-PAC-BRAC-Si-bead aliquots; reactions were performed in duplicate for each bead type.
  • 150 pg of each oligo-PAC-BRAC-Si-magbead type (PCM01-07) was pipetted into wells of a 96 well plate. Beads were pelleted and resuspended in nucleotide addition mix (NAM) before incubation at 37 °C for 5 minutes. Each well was washed twice with a high salt buffer to stop the synthesis reaction and remove reaction components.
  • Oligonucleotide was removed from the bead with uracil DNA glycosylase (UDG). The oligonucleotide was analysed by PAGE and visualised on a Typhoon scanner.
  • N+12 enzymatic synthesis reactions Enzymatic 3'-oxyamine N+12 (SEQ ID NO: 5 - ATCGATCGATCG) nucleotide addition reactions were conducted on each of the oligo-PAC-BRAC-Si-bead aliquots; reactions were conducted in duplicate for each bead-type.
  • 150 pg of each oligo-PAC-BRAC-Si- magbead type (PCM01-07) was pipetted into wells of a 96 well plate. Beads were pelleted and resuspended in nucleotide addition mix (NAM) before incubation at 37 °C for 5 minutes. Each well was washed twice with a high salt buffer to stop the synthesis reaction and remove reaction components.
  • oligonucleotide was then recovered from the beads with uracil DNA glycosylase (UDG). The oligonucleotide was analysed by PAGE and visualised on a Typhoon scanner.
  • Figure 2 shows the PAGE image for N+l addition reactions performed on different PAC-BRAC polymer coated bead types (PCM01-07). The intensity of bands clearly shows that certain bead treatments are beneficial. Plotting the N-band intensity of each bead type ( Figure 3) aids interpretation of the gel image.
  • EXAMPLE 2 Varying the identity of the first co-monomer.
  • Solid support preparation The polymerisation and coating of solid support was performed as described in other examples, with the exception that some or all (0-100%) of the acrylamide comonomer was replaced with either N-(hydroxylmethyl)acrylamide, N-(hydroxyethyl)acrylamide, N,N'- dimethyl acrylamide, or N-[tris(hydroxymethyl)methyl]acrylamide. Oligonucleotide initiator grafting was performed as described in a previous example.
  • N+17 enzymatic synthesis reactions Enzymatic N+17 (SEQ ID NO: 6 - CTTCATGACGTAAGGCC) nucleotide addition reactions were conducted on each of the oligo-xPAC-BRAC-Si-bead aliquots; reactions were conducted in duplicate for each bead-type. 150 pg of each oligo-PAC-BRAC-Si-magbead type was pipetted into wells of a 96 well plate.
  • NAM nucleotide addition mix
  • Figure 7 shows the effect of altering the first co-monomer identity on polymer performance in a method of multicycling enzymatic synthesis.
  • Complete replacement of acrylamide as the first co- monomer with N-[tris(hydroxymethyl)methyl]acrylamide or N,N'-dimethyl acrylamide reduces the synthesis performance obtained on the surface; meanwhile complete replacement with N- (hydroxylmethyl)acrylamide or N-(hydroxyethyl)acrylamide yielded a result comparable to the parent polymer (100% acrylamide as the first co-monomer).
  • a mixed species first copolymer e.g. 50% acrylamide and 50% N-(hydroxymethyl)acrylamide
  • first co-monomer coating can be finely tuned by either altering the identity of the first comonomer or using a mixture of first co-monomers (i.e. a mixture of compounds that form the polymer but do not serve as grafting points for an initiator oligonucleotide).
  • EXAMPLE 3 Preparation of oligonucleotides using the methods of the invention in a frit-retained beads format.
  • the oligo-PAC-BRAC-Si-beads can be used in a method of enzymatic synthesis whereby the solutions are exchanged by means of pelleting the beads using a magnet.
  • the oligo-PAC-BRAC-Si-beads are used in a method of enzymatic synthesis whereby the solutions are exchanged by means of retaining the polymer coated beads with a frit in a well and applying a vacuum to remove the solutions through the frit.
  • PAC-BRAC-Si-beads (100% acrylamide as first co-monomer) were prepared and had oligonucleotide initiators grafted to them as described in Example 1.
  • the synthesised oligonucleotides were then cleaved from the solid support using uracil DNA glycosylase (UDG) and alkaline cleavage of the resulting abasic site.
  • UDG uracil DNA glycosylase
  • the cleaved oligonucleotides were analysed by polyacrylamide gel electrophoresis (PAGE) and visualized by virtue of an internal TAMRA dye on a Typhoon Biomolecular Imager.
  • Figure 8 shows the resulting gel image from representative wells from the 96-well and 384-well fritted plates.
  • An initiator control was run in lane 1 as an N marker.
  • the increase in molecular weight corresponding to the TdT-mediated addition of 8 nucleotides causes the product to migrate slower down the gel giving the major N+8 band (initiator + TTT l l l I T) (SEQ ID NO: 7 -TT l l l l l l l ).
  • Each well of the multiwell plate has a frit as the bottom surface that retains the polymer coated beads while solutions are dispensed into the wells and then removed by application of a vacuum.
  • This set up is analogous to packed bed reactors commonly used in the chemical and biochemical industries.
  • EXAMPLE 4 Preparation of oligonucleotides using the methods of the invention in a polymer coated glass fibre frit format.
  • the oligo-PAC-BRAC-Si-beads can be used in a method of enzymatic synthesis whereby the solutions are exchanged by means of pelleting the beads using a magnet.
  • the glass fibre frit of a multiwell plate is directly coated with pre-polymerised PAC-BRAC and subsequently oligonucleotide initiators are attached. Addition, wash, and deblock solutions are then conveniently exchanged by means of applying a vacuum.
  • the PAC-BRAC polymer solution was prepared as follows. First solution A was formed by combining 125 pL 40% w/v acrylamide solution with 10 mL of ultrapure water. Solution A was then degassed with nitrogen for 20 minutes. Solution B was prepared by dissolving 108.8 mg BRAC in 1080 pL dimethylformamide. Solution C was prepared by dissolving 177 mg potassium persulfate in 3527 pL ultrapure water. Solution B (800 pL) was added to solution A and vortexed to mix. To the combined solution A+B was added 11.5 pL tetramethylethylenediamine following by mixing. Polymerisation was initiated by addition of 100 pL of solution C and brief mixing. The polymerising solution was sealed and kept in the dark for 18 hours. Centrifugation was performed prior to decanting the polymer into a fresh tube.
  • oligonucleotides were then cleaved from the solid support using uracil DNA glycosylase (UDG) and N,N'-dimethylethylenediamine (DMED).
  • UDG uracil DNA glycosylase
  • DMED N,N'-dimethylethylenediamine
  • the cleaved oligonucleotides were analysed by polyacrylamide gel electrophoresis (PAGE) and visualized by virtue of an internal TAMRA dye on a Typhoon Biomolecular Imager.
  • PAGE polyacrylamide gel electrophoresis
  • Figure 9 shows the resulting gel image from representative wells from the 384-well glass fibre fritted plates.
  • An initiator control was run in lane 1 as an N marker.
  • the increase in molecular weight corresponding to the TdT-mediated addition of 8 nucleotides causes the product to migrate slower down the gel giving the major N+8 band (initiator + l l l l l l IT).
  • EXAMPLE 5 Preparation of oligonucleotides using the methods of the invention whereby the solid support comprises only polymerised material that is not coated onto an existing solid material.
  • the polymerised material can be coated onto an existing solid material.
  • the polymerised material may itself act as the solid support, such that the solid support comprises only polymerised material that is not coated onto an existing solid material.
  • polymer only solid support was held in a multiwell plate with a frit so that addition, wash, and deblock solutions could be conveniently exchanged by means of applying a vacuum.
  • Solid support formation First solution A was formed by combining 360g urea, 375 mL of 19:1 acrylamide:bisacrylamide, 75 mL 10X TBE buffer, and 25 mL water.
  • Solution B was formed by adding 2 g of SPAN85 to 200 mL hexane and degassing.
  • Solution C was formed by dissolving 52.3 mg potassium persulfate in 523 pL ultrapure water. 10 pL of 100 pM m5'-methacrylate oligonucleotide was combined with 10 mL of solution A. To this solution was added 56.7 pL solution C and 4 pL tetramethylethylenediamine. After 5 minutes the combined solution was added to solution B and stirred rapidly for one hour. The polymer beads that formed were allowed to settle before the supernatant was decanted and the beads washed with 20 mL ethanol. Finally, the polymer beads were dialysed prior to use.
  • Enzymatic DNA synthesis was performed on a Tecan Freedom Evo 200 liquid handling system in a 96- well PVDF 0.22 ⁇ m filter plate. An automated workflow analogous to that used in Example 3 was employed, with appropriate changes to enable synthesis of the sequence ATCGATCG. Following completion of synthesised, the oligonucleotides were prepared into next-generation sequencing libraries and run on an Illumina iSeq 100.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des procédés améliorés de synthèse enzymatique d'acides nucléiques à support solide qui utilisent des enzymes de désoxynucléotidyl transférase terminale (TdT) ou des enzymes de désoxynucléotidyl transférase terminale (TdT) modifiées sur des supports de type polyacrylamide. L'invention concerne en outre l'utilisation de kits comprenant lesdites enzymes dans un procédé de synthèse d'acides nucléiques à support solide.
PCT/GB2021/052189 2020-08-21 2021-08-23 Synthèse d'acides nucléiques à support solide de type polyacrilamide WO2022038386A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP21769161.7A EP4200411A1 (fr) 2020-08-21 2021-08-23 Synthèse d'acides nucléiques à support solide de type polyacrilamide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2013102.5A GB202013102D0 (en) 2020-08-21 2020-08-21 Methods of nucleic acid synthesis
GB2013102.5 2020-08-21

Publications (1)

Publication Number Publication Date
WO2022038386A1 true WO2022038386A1 (fr) 2022-02-24

Family

ID=72660840

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2021/052189 WO2022038386A1 (fr) 2020-08-21 2021-08-23 Synthèse d'acides nucléiques à support solide de type polyacrilamide

Country Status (3)

Country Link
EP (1) EP4200411A1 (fr)
GB (1) GB202013102D0 (fr)
WO (1) WO2022038386A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118127102A (zh) * 2024-05-10 2024-06-04 天津凯莱英生物科技有限公司 酶法合成具有3’-o-磷酸修饰的核酸的方法

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005065814A1 (fr) 2004-01-07 2005-07-21 Solexa Limited Arrangements moleculaires modifies
US20160108382A1 (en) * 2014-10-20 2016-04-21 Molecular Assemblies, Inc. Modified template-independent enzymes for polydeoxynucleotide synthesis
WO2016128731A1 (fr) * 2015-02-10 2016-08-18 Nuclera Nucleics Ltd Nouvelle utilisation
EP3249057A1 (fr) 2013-03-14 2017-11-29 Life Technologies Corporation Réseaux matriciels et leurs procédés de fabrication
WO2018134616A1 (fr) * 2017-01-19 2018-07-26 Oxford Nanopore Technologies Limited Procédés et réactifs de synthèse de molécules polynucléotidiques
WO2018138508A1 (fr) * 2017-01-27 2018-08-02 Nuclera Nucleics Ltd Triphosphates nucléotidiques immobilisés sur un support et leur utilisation dans la synthèse d'acides nucléiques
WO2018215803A1 (fr) 2017-05-26 2018-11-29 Nuclera Nucleics Ltd Utilisation d'enzyme transférase terminale dans la synthèse d'acides nucléiques
WO2019053443A1 (fr) 2017-09-14 2019-03-21 Nuclera Nucleics Ltd Nouvelle utilisation
WO2019224544A1 (fr) * 2018-05-23 2019-11-28 Oxford Nanopore Technologies Limited Procédé, système et kit de synthèse de polynucléotides
WO2020016605A1 (fr) * 2018-07-19 2020-01-23 Oxford Nanopore Technologies Limited Procédé de synthèse de polynucléotides, kit et système associés
WO2020016606A1 (fr) 2018-07-19 2020-01-23 Oxford Nanopore Technologies Limited Procédé, kit et système de synthèse de polynucléotides
WO2020150143A2 (fr) 2019-01-14 2020-07-23 Camena Bioscience Limited Compositions et procédés de synthèse d'acide nucléique enzymatique géométrique sans matrice
WO2020165137A1 (fr) 2019-02-12 2020-08-20 Dna Script Clivage efficace de produit dans la synthèse enzymatique sans matrice de polynucléotides

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005065814A1 (fr) 2004-01-07 2005-07-21 Solexa Limited Arrangements moleculaires modifies
EP3249057A1 (fr) 2013-03-14 2017-11-29 Life Technologies Corporation Réseaux matriciels et leurs procédés de fabrication
US20160108382A1 (en) * 2014-10-20 2016-04-21 Molecular Assemblies, Inc. Modified template-independent enzymes for polydeoxynucleotide synthesis
WO2016128731A1 (fr) * 2015-02-10 2016-08-18 Nuclera Nucleics Ltd Nouvelle utilisation
WO2018134616A1 (fr) * 2017-01-19 2018-07-26 Oxford Nanopore Technologies Limited Procédés et réactifs de synthèse de molécules polynucléotidiques
WO2018138508A1 (fr) * 2017-01-27 2018-08-02 Nuclera Nucleics Ltd Triphosphates nucléotidiques immobilisés sur un support et leur utilisation dans la synthèse d'acides nucléiques
WO2018215803A1 (fr) 2017-05-26 2018-11-29 Nuclera Nucleics Ltd Utilisation d'enzyme transférase terminale dans la synthèse d'acides nucléiques
WO2019053443A1 (fr) 2017-09-14 2019-03-21 Nuclera Nucleics Ltd Nouvelle utilisation
WO2019224544A1 (fr) * 2018-05-23 2019-11-28 Oxford Nanopore Technologies Limited Procédé, système et kit de synthèse de polynucléotides
WO2020016605A1 (fr) * 2018-07-19 2020-01-23 Oxford Nanopore Technologies Limited Procédé de synthèse de polynucléotides, kit et système associés
WO2020016606A1 (fr) 2018-07-19 2020-01-23 Oxford Nanopore Technologies Limited Procédé, kit et système de synthèse de polynucléotides
WO2020150143A2 (fr) 2019-01-14 2020-07-23 Camena Bioscience Limited Compositions et procédés de synthèse d'acide nucléique enzymatique géométrique sans matrice
WO2020165137A1 (fr) 2019-02-12 2020-08-20 Dna Script Clivage efficace de produit dans la synthèse enzymatique sans matrice de polynucléotides

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ACS NANO, vol. 12, no. 6, 2018, pages 6050 - 6058
J. ADHES. SCI. TECHNOL., vol. 26, 2012, pages 1747 - 1771
LAB CHIP, vol. 19, 2019, pages 2275
RSC ADV., vol. 7, 2017, pages 49633 - 49648

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118127102A (zh) * 2024-05-10 2024-06-04 天津凯莱英生物科技有限公司 酶法合成具有3’-o-磷酸修饰的核酸的方法

Also Published As

Publication number Publication date
GB202013102D0 (en) 2020-10-07
EP4200411A1 (fr) 2023-06-28

Similar Documents

Publication Publication Date Title
JP7203893B2 (ja) 固形支持体でのサンプル調製
US11618808B2 (en) Catalyst-free surface functionalization and polymer grafting
EP3329012B1 (fr) Cartographie spatiale d'informations de séquence d'acide nucléique
US10941439B2 (en) Substrates and methods useful in sequencing
EP2657869A2 (fr) Procédé de séquencage alternatif d'acide nucléique
EP2028272B1 (fr) Procede de modification d'une chaine de nucleotides
EP3265468A1 (fr) Procédé de synthèse d'acide nucléique par l'intermédiaire d'un 3'-o-azidométhylnucléotide triphosphate
US12006543B2 (en) Device preparation using condensed nucleic acid particles
WO2019084058A2 (fr) Support solide fonctionnalisé
EP3935187B1 (fr) Procédé de synthèse d'oligonucléotide
EP4200411A1 (fr) Synthèse d'acides nucléiques à support solide de type polyacrilamide
US20230117083A1 (en) Methods of nucleic acid synthesis
US6942974B2 (en) Selective elution of immobilized multiplexed primer extension products
EP4196603A1 (fr) Procédés se rapportant à la synthèse enzymatique de novo d'acides nucléiques
WO2020234605A1 (fr) Procédé de contrôle de qualité de synthèse d'oligonucléotides
CA2473308C (fr) Dosage et kit d'analyse d'expression genique
WO2023240090A1 (fr) Amélioration de l'efficacité et de la cinétique de regroupement

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21769161

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021769161

Country of ref document: EP

Effective date: 20230321